BioSpecifics Technologies Corp

Type: Company
Name: BioSpecifics Technologies Corp
First reported Oct 21 2014 - Updated Oct 21 2014 - 4 reports

BioSpecifics Technologies Corp announces FDA approval of sBLA for XIAFLEX for concurrent treatment of two dupuytren's contracture cords

8:00am EDTBioSpecifics Technologies Corp:Says U.S. FDA has approved supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX.Says XIAFLEX, for treatment of up to two Dupuytren's ... [Published Reuters - Oct 21 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

BioSpecifics Technologies Corp engages EisnerAmper LLP as new independent registered public accounting firm - Form 8-K

11:01am BSTBioSpecifics Technologies Corp:Audit Committee of company recently completed process to select audit firm that would serve as company's independent registered public accounting firm beginning with quarter ending Sept. 30, 2014.As previously ... [Published Reuters UK - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 4 reports

BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine

LYNBROOK, N.Y."The preclinical data presented today are very promising and contribute to the much needed development of a non-surgical treatment option for uterine fibroids," commented Thomas L. WegmanThe preclinical results were presented by Dr. Friederike ... [Published Bio-Medicine - Oct 16 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 3 reports

BioSpecifics Technologies Corp. Announces Sudden Passing of Director Max Link, Ph.D.

"We are very saddened by the sudden passing of Max LinkDr. Link served as a Director for many distinguished pharmaceutical and biotech companies including CytRx, Alexion and Celsion. He earned a Ph.D. in economics from the University of St. Gallen.The ... [Published Industrial Info Financials - Oct 08 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Biospecifics Technologies - Barchart's Chart Of The Day

0 comments Oct 2, 2014 4:57 PM| about stocks: BSTCThe Chart of the Day belongs to Biospecifics Technologies (NASDAQ: BSTC ). I found the stock by sorting the All Time New High list for the highest technical buy signals then used the Flipchart feature ... [Published Seeking Alpha - Oct 02 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 3 reports

BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference

About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase ... [Published Industrial Info Financials - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

BioSpecifics Technologies Corp. Announces New MULTICORD and Retreatment Data for XIAFLEX® for Dupuytren's Contracture Presented at American Society for Surgery of the Hand Annual Meeting

LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: General Business - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

BioSpecifics Technologies Corp. Sets New 12-Month High at $33.75 (BSTC)

BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s share price hit a new 52-week high during mid-day trading on Wednesday , AnalystRatings.NET reports. The stock traded as high as $33.75 and last traded at $33.61, with a volume of 60,135 shares. The stock ... [Published American Banking News - Sep 17 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences

LYNBROOK, N.Y., Sept. 2, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ... [Published PR Newswire: Health - Sep 02 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 2 reports

BioSpecifics’ Xiaflex demonstrates efficacy in Phase 2a cellulite study

BioSpecifics Technologies’ collagenase clostridium histolyticum showed promise for smoothing cellulite during a recent randomized, double-blind Phase 2a study in the US. ... [Published PBR - News - Aug 22 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results

LYNBROOK, N.Y., Aug. 11, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: Financial Services - Aug 11 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 1 reports

BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014

LYNBROOK, N.Y., Aug. 4, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: Health - Aug 04 2014]

Quotes

"We are very excited by this label expansion for XIAFLEX as it allows physicians to treat more than one Dupuytren's cord at the same time, bringing added convenience to the physician and offering broadened treatment options to patients who would prefer to avoid an invasive surgical procedure. Market share of XIAFLEX for Dupuytren's contracture has been steadily increasing, across all procedures, and we believe this label expansion will lead to even more growth since it is estimated that 35 to 40 percent of Dupuytren's surgeries treat more than one cord" commented Thomas Wegman, President of BioSpecifics
"The preclinical data presented today are very promising and contribute to the much needed development of a non-surgical treatment option for uterine fibroids" commented Thomas L Wegman
...to the much needed development of a non-surgical treatment option for uterine fibroids," commented Thomas L Wegman , President of BioSpecifics. "Accumulation of collagen in uterine fibroid tumors is thought to contribute to the many morbidities associated with the condition and we aim to further show how CCH can lead to improved patient outcomes. We are working on our development plans for this indication and will update you once we have those finalized."

More Content

All (34) | News (14) | Reports (0) | Blogs (18) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
BioSpecifics Technologies Corp announces FDA ap... [Published Reuters - Oct 21 2014]
BioSpecifics Tech. Reports FDA Approval Of SBLA... [Published RTTNews.com - Oct 21 2014]
BioSpecifics Technologies Corp. Announces FDA A... [Published Myrtle Beach Sun News - Oct 21 2014]
BioSpecifics Technologies Corp. Announces FDA A... [Published PR Newswire: Policy & Public Interest - Oct 21 2014]
BioSpecifics Technologies Corp engages EisnerAm... [Published Reuters UK - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Bio-Medicine - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Fat Pitch Financials - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Stock Nod - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: Health - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Sudde... [Published Industrial Info Financials - Oct 08 2014]
BioSpecifics Technologies Corp. Announces Sudde... [Published Town Hall - Oct 08 2014]
BioSpecifics Technologies Corp. Announces Sudde... [Published PR Newswire: General Business - Oct 08 2014]
Biospecifics Technologies - Barchart's Chart Of... [Published Seeking Alpha - Oct 02 2014]
BioSpecifics Technologies Corp. to Present at t... [Published Industrial Info Financials - Sep 19 2014]
BioSpecifics Technologies : to Present at the 2... [Published 4 Traders - Sep 19 2014]
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: General Business - Sep 19 2014]
BioSpecifics Technologies Corp. Announces New M... [Published PR Newswire: General Business - Sep 18 2014]
BioSpecifics Technologies Corp. Sets New 12-Mon... [Published American Banking News - Sep 17 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: Health - Sep 02 2014]
BioSpecifics’ Xiaflex demonstrates efficacy in ... [Published PBR - News - Aug 22 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Aug 21 2014]
BioSpecifics Technologies Corp. Reports Second ... [Published PR Newswire: Financial Services - Aug 11 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published PR Newswire: Health - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - Aug 04 2014]
BioSpecifics Technologies Corp (NASDAQ: BSTC) t... [Published GlobeNewswire: Advertising News - Jul 22 2014]
Corporate Updates, Certifications, and Product ... [Published PR Newswire: Financial Services - Jul 02 2014]
BioSpecifics Technologies Corp. to Be Added to ... [Published PR Newswire: Health - Jun 27 2014]
BioSpecifics Technologies Corp. Announces Filin... [Published PR Newswire: Health - Jun 25 2014]
BioSpecifics Announces New Analyses of XIAFLEX ... [Published PR Newswire: Health - May 19 2014]
1 2
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioSpecifics Technologies Corp. Announces FDA A... [Published PR Newswire: Policy & Public Interest - Oct 21 2014]
LYNBROOK, N.Y., Oct. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the ...
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: Health - Oct 16 2014]
LYNBROOK, N.Y., Oct. 16, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the ...
BioSpecifics Technologies Corp. Announces Sudde... [Published PR Newswire: General Business - Oct 08 2014]
LYNBROOK, N.Y., Oct. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), today announced with great sadness that Max Link, Ph.D., a member of its Board of Directors, passed away unexpectedly on October 5, 2014. He was 74 years old. ...
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: General Business - Sep 19 2014]
LYNBROOK, N.Y., Sept. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
BioSpecifics Technologies Corp. Announces New M... [Published PR Newswire: General Business - Sep 18 2014]
LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
1 2 3 4

Press Releases

sort by: Date | Relevance
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
BioSpecifics Technologies Corp (NASDAQ: BSTC) t... [Published GlobeNewswire: Advertising News - Jul 22 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.